One concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.

A narrower follow-up, since the general answer is now clear:

What actually belongs on a baseline panel, as opposed to the enormous list that gets pasted around here?

kate.chem said:

With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most…

There is a second half to this that has not been said yet. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.

That is the short version; the long version is somebody else's post.

Closing the loop on my own question.

Took the whole panel in rather than the one flagged line, and the conversation lasted two minutes instead of generating three more tests.

TrialNerd_Beth said:

The liver data is among the strongest non-weight findings in the class.

That is correct as far as it goes, and here is where it stops going. One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.